Abel Hall LLC
AARD icon

Abel Hall LLC’s Aardvark Therapeutics AARD Stock Holding History

Abel Hall LLC’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$53K Hold
10,066
– – 0.01% 832
2026
Q2 		$58K Buy
+10,066
New +$47K 0.01% 888

Other funds holding AARD

Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
Stone House Investment Management
Stone House Investment Management Tunkhannock, Pennsylvania $768M AUM 12.07% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Hilton Head Capital Partners
Hilton Head Capital Partners Hilton Head Island, South Carolina $185M AUM 26.97% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Abel Hall LLC's AARD Position: Q3 2026 in Review

Abel Hall LLC held its Aardvark Therapeutics (AARD) position steady in Q3 2026 at 10,066 shares worth $53K. The position accounts for 0.01% of the portfolio, ranked #832.

Abel Hall LLC first reported a position in AARD in Q2 2026 and has held it in 2 quarters since. The position peaked at $58K in Q2 2026. 14 funds tracked by Wall St. Rank hold AARD as of Q3 2026.

  • Abel Hall LLC held 10,066 shares of Aardvark Therapeutics worth $53K as of Q3 2026.
  • Abel Hall LLC left its Aardvark Therapeutics share count unchanged in Q3 2026.
  • Aardvark Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q3 2026, its #832 holding.
  • Abel Hall LLC first reported a position in Aardvark Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Abel Hall LLC's Aardvark Therapeutics position peaked at $58K in Q2 2026.
  • 14 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.